Calquence (acalabrutinib)

pCPA File Number: 23334

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant.

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0413-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable